Detalhe da pesquisa
1.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 23(7): 876-887, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35636444
2.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Oncologist
; 26(4): 302-309, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33336844
3.
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Br J Cancer
; 123(3): 403-409, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32424148
4.
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
BMC Cancer
; 20(1): 683, 2020 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32698790
5.
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
Eur J Cancer
; 184: 106-116, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36913832
6.
Exploring the Outcome of Disappearance or Small Remnants of Colorectal Liver Metastases during First-Line Chemotherapy on Hepatobiliary Contrast-Enhanced and Diffusion-Weighted MR Imaging.
Cancers (Basel)
; 15(8)2023 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37190129
7.
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.
Tumori
; 109(5): 481-489, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36609197
8.
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Eur J Cancer
; 189: 112910, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37301718
9.
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
J Immunother Cancer
; 11(4)2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37085190
10.
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.
Front Oncol
; 13: 1307545, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38406172
11.
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Clin Cancer Res
; 29(12): 2291-2298, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37022350
12.
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients.
Cancers (Basel)
; 14(18)2022 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36139613
13.
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.
Eur J Cancer
; 161: 90-98, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34933155
14.
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
Eur J Cancer
; 168: 34-40, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35436675
15.
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Cancer Treat Rev
; 103: 102326, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35016085
16.
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO.
Clin Colorectal Cancer
; 21(3): 220-228, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35304089
17.
Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.
JCO Precis Oncol
; 6: e2200037, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35544729
18.
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Eur J Cancer
; 170: 64-72, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35594613
19.
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.
Eur J Cancer
; 165: 116-124, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35231767
20.
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
Eur J Cancer
; 167: 23-31, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35366570